Zydus Lifesciences gets final nod to manufacture, market Lacosamide Tablets

16 Dec 2023 Evaluate

Zydus Lifesciences (including its subsidiaries/affiliates, hereafter referred to as ‘Zydus’) has received final approval from the United States Food and Drug Administration (USFDA) to manufacture and market Lacosamide Tablets USP, 50 mg, 100 mg, 150 mg, and 200 mg (USRLD: Vimpat Tablets).

Lacosamide is indicated to treat partial-onset seizures. It is also used with other medicines to treat primary generalized tonic-clonic seizures. The product will be manufactured at the group’s formulation manufacturing facility in Moraiya, Ahmedabad (India). Lacosamide Tablets USP, 50 mg, 100 mg, 150 mg, and 200 mg had annual sales of $249 million in the United States (IQVIA December. October. 2023).

The group now has 384 approvals and has so far filed over 448 ANDAs since the commencement of the filing process in FY 2003-04.

Zydus Lifesciences (formerly known as Cadila Healthcare) is an India-based pharmaceutical company.

Zydus Lifesciences Share Price

931.45 -3.75 (-0.40%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×